Tyme Technologies Inc (TYME) CEO Sells $68,706.52 in Stock
Tyme Technologies Inc (NASDAQ:TYME) CEO Steve Hoffman sold 17,986 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $3.82, for a total value of $68,706.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Tyme Technologies Inc (NASDAQ TYME) traded down $0.24 during mid-day trading on Wednesday, reaching $3.41. The company had a trading volume of 193,036 shares, compared to its average volume of 168,856. The stock has a market cap of $332.70, a price-to-earnings ratio of -21.47 and a beta of -0.59. Tyme Technologies Inc has a one year low of $2.14 and a one year high of $9.50.
TYME has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Tyme Technologies in a research note on Friday, December 15th. They issued a “buy” rating and a $8.00 target price for the company. Evercore ISI initiated coverage on Tyme Technologies in a research note on Friday, November 17th. They issued an “outperform” rating and a $7.00 target price for the company. BidaskClub upgraded Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Finally, Canaccord Genuity initiated coverage on Tyme Technologies in a research note on Wednesday, January 3rd. They issued a “buy” rating for the company.
TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/tyme-technologies-inc-tyme-ceo-sells-68706-52-in-stock.html.
Tyme Technologies Company Profile
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.